Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: HER2-expressing Cancers
Interventions: DRUG: ZW25 (Zanidatamab)|DRUG: Paclitaxel|DRUG: Capecitabine|DRUG: Vinorelbine|DRUG: Tucatinib|DRUG: Tucatinib
Sponsor: Jazz Pharmaceuticals